This clinical trial is focused on studying Idiopathic Pulmonary Fibrosis (IPF), a lung disease that causes scarring of the lungs, making it difficult to breathe. The trial will evaluate a new treatment called GSK3915393, which is a film-coated tablet taken by mouth. The purpose of the study is to assess how effective and safe this medication is in reducing the decline in lung volume for people with IPF.
Participants in the study will be randomly assigned to receive either the GSK3915393 tablet or a placebo, which looks like the real medication but does not contain the active substance. The study will last for about 26 weeks, during which participants will take the medication regularly and attend scheduled visits to monitor their health and lung function. The main focus will be on measuring changes in lung capacity over time.
Throughout the study, participants will undergo various health checks, including assessments of vital signs like blood pressure and heart rate, as well as laboratory tests to ensure their safety. The trial aims to provide valuable information on whether GSK3915393 can help slow down the progression of Idiopathic Pulmonary Fibrosis and improve the quality of life for those affected by this condition.
France 
Germany 
Italy 
Poland 
Spain 
The Netherlands 
